CHARLOTTE — A federal judge granted summary judgment in favor of Merck for part of the litigation involving the HPV vaccine, Gardasil. The rest of the case is still going on. 2022: Local women ...

225,000-square-foot manufacturing plant that will produce bulk substance for Merck's Gardasil HPV vaccine. Merck has spent a total of more than $12 billion in expanding its U.S. manufacturing and ...

Rising competitive pressure on the diabetes franchise and persistent challenges for its human papillomavirus vaccine, Gardasil in China remain overhangs. There are concerns about Merck’s ability ...

CASE DETAILS: According to the complaint, defendants provided investors with material information concerning Merck's expected revenue of $11 billion from sales of Gardasil by 2030. Defendants ...

Although Keytruda is a huge part of its business, Merck does have other products that can also generate billions in revenue in the future. Gardasil, its vaccine for the human papillomavirus (HPV ...

There is ongoing litigation against Merck, the maker of Gardasil, due to accusations that the company concealed the risks of the vaccine. The plaintiffs claim that Merck should've added warnings ...

CASE DETAILS: According to the complaint, defendants provided investors with material information concerning Merck's expected revenue of $11 billion from sales of Gardasil by 2030. Defendants ...

What are Merck's top-selling medications and vaccines? They are Keytruda, Gardasil/Gardasil 9, ProQuad/M-M-R II/Varivax, Animal Health segment, and Bridion. Their total sales were $11.8 billion ...

With the CSF-1R inhibitor space heating up, Merck KGaA has gone all-in on pimicotinib ... the upfront fees as well as development and commercial milestones—alongside a share of royalties ...

Meanwhile, shares of its pharmaceutical rival Merck (NYSE: MRK) have lagged, down 8% in the same period. Amgen shareholders are celebrating, but have you wondered which stock is cheaper right now?